NCT03745729

Allopurinol in Acute Coronary Syndrome

A Single-center, Prospective, Randomized, Double-blind, Controlled Trial for the Effect of Allopurinol Sustained-release Capsules on the Stability of Coronary Plaques in Patients With Acute Coronary Syndrome

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 162 (actual)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The pathogenesis of coronary heart disease is closely related to inflammation. IL-1 beta is an effective target for anti-inflammatory treatment of coronary heart disease. Allopurinol is a drug used for treating hyperuricemia and gout for many years. Recently, allopurinol has been proved to inhibit the production of NLRP3 in monocytes and reduce the level of IL-1beta, resulting in the decrease of TNF-alpha, IL-6 and CRP. Thus, in this study, the investigators aim to evaluate the efficacy and safety of allopurinol sustained-release capsules on improving the stability of coronary plaque in patients with acute coronary syndrome treated by conventional standardized therapy by the single-center, prospective, randomized, double-blind and controlled methods, which would provide new strategies for the treatment of coronary heart disease.

Conditions

• Acute Coronary Syndrome

Interventions

Type	Name	Description
DRUG	allopurinol sustained-release capsules	allopurinol sustained-release capsules (0.25g), once a day, one pill at a time
DRUG	placebo capsules	placebo sustained-release capsules, once a day, one pill at a time

Timeline

• Start date: 2019-03-01
• Primary completion: 2022-07-15
• Completion: 2022-07-15
• First posted: 2018-11-19
• Last updated: 2022-09-16

Locations

1 site across 1 country: China